{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:42:24Z","timestamp":1792449744142,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.14283\/jpad.2021.56","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T01:36:15Z","timestamp":1631669775000},"page":"414-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging"],"prefix":"10.1016","volume":"8","author":[{"given":"S.L.","family":"Lowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Duggan Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shcherbinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-J.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Gueorguieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.","family":"Fleisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ardayfio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ishibai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Takaichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mullins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.14283\/jpad.2021.56_bib1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrd3505","article-title":"The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics","volume":"10","author":"Karran","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.14283\/jpad.2021.56_bib2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.trci.2019.05.008","article-title":"Alzheimer's disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"9","key":"10.14283\/jpad.2021.56_bib3","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"5","key":"10.14283\/jpad.2021.56_bib4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"issue":"1","key":"10.14283\/jpad.2021.56_bib5","doi-asserted-by":"crossref","first-page":"e12112","DOI":"10.1002\/trc2.12112","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer's disease","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"10.14283\/jpad.2021.56_bib6","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"23","key":"10.14283\/jpad.2021.56_bib7","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1001\/jama.2011.810","article-title":"Changing concepts of Alzheimer disease","volume":"305","author":"McKhann","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.14283\/jpad.2021.56_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","article-title":"Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study","volume":"10","author":"Barthel","year":"2011","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.14283\/jpad.2021.56_bib9","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"1\u20132","key":"10.14283\/jpad.2021.56_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jim.2007.07.004","article-title":"An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug","volume":"327","author":"Bourdage","year":"2007","journal-title":"J Immunol Methods"},{"issue":"12","key":"10.14283\/jpad.2021.56_bib11","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.4155\/bio.10.136","article-title":"Comparison of assay formats for drug-tolerant immunogenicity testing","volume":"2","author":"Butterfield","year":"2010","journal-title":"Bioanalysis"},{"key":"10.14283\/jpad.2021.56_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jim.2016.02.008","article-title":"Affinity capture elution bridging assay: A novel immunoassay format for detection of anti-therapeutic protein antibodies","volume":"431","author":"Chen","year":"2016","journal-title":"J Immunol Methods"},{"issue":"20","key":"10.14283\/jpad.2021.56_bib13","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.4155\/bio-2016-0161","article-title":"An innovative and highly drug-tolerant approach for detecting neutralizing antibodies directed to therapeutic antibodies","volume":"8","author":"Sloan","year":"2016","journal-title":"Bioanalysis"},{"issue":"3","key":"10.14283\/jpad.2021.56_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.2010.2008","article-title":"Use of florbetapir-PET for imaging beta-amyloid pathology","volume":"305","author":"Clark","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.14283\/jpad.2021.56_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.14283\/jpad.2021.56_bib16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"issue":"7618","key":"10.14283\/jpad.2021.56_bib17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.14283\/jpad.2021.56_bib18","doi-asserted-by":"crossref","first-page":"P1668","DOI":"10.1016\/j.jalz.2018.07.009","article-title":"DT-01-07: Treatment of early AD subjects with BAN2401, an anti-A\u03b2 protofibrial monoclonal antibody, significantly clears amyloid plaque and reduces clinical decline","volume":"14","author":"Swanson","year":"2018","journal-title":"Alzheimer's & Dementia"},{"issue":"1","key":"10.14283\/jpad.2021.56_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"10.14283\/jpad.2021.56_bib20","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/brain\/awaa332","article-title":"BACE inhibition causes rapid, regional, and nonprogressive volume reduction in Alzheimer's disease brain","volume":"143","author":"Sur","year":"2020","journal-title":"Brain"},{"issue":"1","key":"10.14283\/jpad.2021.56_bib21","doi-asserted-by":"crossref","first-page":"e12123","DOI":"10.1002\/trc2.12123","article-title":"Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease","volume":"7","author":"Zimmer","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"10.14283\/jpad.2021.56_bib22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3233\/JAD-150448","article-title":"Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease","volume":"49","author":"Novak","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.14283\/jpad.2021.56_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2021.56_bib24","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","author":"Mintun","year":"2021","journal-title":"N Engl J Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724005387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:14:02Z","timestamp":1737339242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724005387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2274580724005387"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2021.56","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2021.56","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}